AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval
Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.
You may also be interested in...
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.